



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Zyprexa

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency's update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, please also refer to **EPAR - Procedural steps taken and scientific information after authorisation (archive)**.

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
Variation type IB /	This was an application for a group of	05/06/2025	N/A	SmPC, Annex	

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



EMA/VR/0000252667	<p>variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.b Primary packaging site - Accepted</p> <p>B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted</p> <p>B.II.b.2.c Replacement or addition of a manufacturer responsible for importation and/or batch release - B.II.b.2.c.2 Including batch control/testing - Accepted</p> <p>B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.a Replacement or addition of a site where batch control/testing takes place - Accepted</p> <p>B.II.b.2.c Replacement or addition of a manufacturer responsible for importation and/or batch release - B.II.b.2.c.1 Not including batch control/testing - Accepted</p>			II and PL	
-------------------	--	--	--	-----------	--

	<p>B.II.e.1.a Qualitative and quantitative composition - B.II.e.1.a.1. Solid pharmaceutical forms - Accepted</p> <p>B.II.d.2 Change in test procedure for the finished product - B.II.d.2.e Update of the test procedure to comply with the updated general monograph in the Ph. Eur. - Accepted</p> <p>B.II.d.2 Change in test procedure for the finished product - B.II.d.2.d Other changes to a test procedure (including replacement or addition) - Accepted</p> <p>B.II.d.2 Change in test procedure for the finished product - B.II.d.2.d Other changes to a test procedure (including replacement or addition) - Accepted</p> <p>B.II.d.2 Change in test procedure for the finished product - B.II.d.2.d Other changes to a test procedure (including replacement or addition) - Accepted</p>				
--	--	--	--	--	--